Acute Lymphoblastic Leukemia: From...
31 Aug,2026
Acute Lymphoblastic Leukemia: From Genetic Complexity to Molecular Clarity
Understanding the Disease
Acute lymphoblastic leukemia (ALL) is a blood cancer characterized by uncontrolled growth of abnormal immature lymphoid cells which disturbs the normal blood-cell growth. ALL is initiated by genetic changes that interfere with the normal differentiation of B- and T-cells.
ALL is genetically heterogenous, with different chromosomal translocations and fusion genes affecting cellular processes, prognosis and treatment decisions.
The genetic heterogeneity poses a diagnostic challenge because patients with similar clinical features may have different molecular abnormalities. Identification of these genetic alterations are important in the overall evaluation and management of ALL.
🌍 Every year about 4,00,000 children and adolescents (0–19 years) develop cancer worldwide.
🩸 Leukemias are among the most common childhood cancers.
📈In high income countries, the cure rate for children with cancer exceeds 80%.
⚠️ In many low and middle income countries cure rates are less than 30%
🔬 Delay or inaccuracy of diagnosis can result in preventable death.
🎯 Better childhood cancer outcomes indicate better access to accurate and timely diagnosis.
Diagnosis of ALL: Why Molecular Testing Matters
The diagnosis of Acute Lymphoblastic Leukemia (ALL) is not just the identification of abnormal lymphoid cells. Molecular testing assists in defining distinct genetic subtypes that may provide important information for diagnosis, prognosis and treatment planning. ALL is linked with several recurrent chromosomal rearrangements and fusion genes, whose frequency varies by age group and population.
The TRUPCR® ALL Panel Kit detects clinically relevant fusion genes including E2A-PBX1, TEL-AML1, MLL-AF4, MLL-ENL, MLL-AF9, MLL-AF6, MLL-AF10 and BCR-ABL1.
Key Markers in ALL
· TEL-AML1 (ETV6-RUNX1): One of the most common changes seen in childhood B-ALL, present in 20-25% of paediatric cases. It is predominantly seen in younger children.
· E2A-PBX1 (TCF3-PBX1): It is present in 5-7% of childhood B-ALL, representing a distinct molecular subtype.
· BCR-ABL1: It occurs in approximately 2-5% of paediatric ALL and up to 20-30% of adult ALL. Its identification is clinically important because it supports targeted tyrosine kinase inhibitor-based therapy.
· MLL/KMT2A rearrangements: Particularly common in infant ALL and usually associated with a higher risk disease profile.
Together these changes make the case that ALL should not be considered a single molecular disease. The nature of the fusion gene identified can provide valuable insight into disease classification, prognosis and therapeutic approach.
TRUPCR® ALL Panel Kit: A Multi-Gene Molecular Approach
The TRUPCR® ALL Panel Kit is a multi-gene panel based on Real-Time PCR for the qualitative detection of diagnostic and prognostic markers associated with acute lymphoblastic leukemia (ALL). The panel permits the molecular testing of multiple clinically relevant fusion genes in a single assay which can allow a more comprehensive genetic characterization of the disease.
For BCR-ABL1, the panel is designed to detect the major (p210), minor (p190) and micro (p230) transcript variants, enabling detection of the different BCR-ABL1 molecular forms.
In a clinical correlation study of 116 samples, the kit showed a sensitivity of 98.00% and a specificity of 98.48% against the reference method.
Conclusion
The genetic diversity of ALL makes molecular characterization an important component of modern diagnosis. Identifying specific fusion genes can help distinguish molecular subtypes and provide clinically relevant information beyond morphology and immunophenotyping. A multi-gene molecular panel brings these important genetic markers together, helping provide greater clarity in the diagnosis and characterization of ALL.
Research That Matters
• Retrospective Study of B Lymphoblastic Leukemia to Assess the Prevalence of TEL/AML1 in South India: A Study of 214 Cases and Review of Literature. Sandhya Devi G. Faiq Ahmed Manasi C. Mundada.
